Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,293 recalls, newest first

Class II · Moderate risk

MAGnesium 1gm sulfate

Labeling: Incorrect or Missing Lot and/or Exp Date:The product labels contain a Two-Dimensional ( 2D ) barcode that, when scanned, reveals information specific to the batch of the labeled product, including Expiration Date. The expiration date included within these 2D barcodes is incorrect and does not match the correct expiration date listed on the face of the label itself.

Terminated Labeling / mix-up Avella of Deer Valley, Inc. Store 38 NDC 42852-901-05 D-0998-2019
Class II · Moderate risk

Labetalol 20mg

Labeling: Incorrect or Missing Lot and/or Exp Date:The product labels contain a Two-Dimensional ( 2D ) barcode that, when scanned, reveals information specific to the batch of the labeled product, including Expiration Date. The expiration date included within these 2D barcodes is incorrect and does not match the correct expiration date listed on the face of the label itself.

Terminated Labeling / mix-up Avella of Deer Valley, Inc. Store 38 NDC 42852-822-71 D-0997-2019
Class III · Low risk

Mometasone Furoate Cream

Labeling: Not Elsewhere Classified. Mometasone Furoate Cream has an NDC typographical error.

Terminated Labeling / mix-up ACP Nimble Buyer, Inc. NDC 0713-0726-37 D-0514-2019
Class II · Moderate risk

LET Gel 4%

Labeling: Incorrect or Missing Lot and/or Exp Date: Labels are missing lot and expiration date and are printed as Lot# YYYDDYY@XX with a Beyond Use Date: MM/DD/YYY.

Terminated Labeling / mix-up US Compounding Inc D-0482-2019
Class II · Moderate risk

Docusate Sodium

Labeling: Label mix-up: Secondary carton may be labeled as Gabapentin 300mg instead of Docusate Sodium 100mg softgel caps.

Terminated Labeling / mix-up Rx Pak Division of McKesson Corporation NDC 63739-0478-10 D-1007-2019
Class II · Moderate risk

HEPERAIN 50 mg/50 mL

Labeling; Label Error on Declared Strength; label incorrectly states the concentration as 50 mg/50 mL (1 mg/mL) rather than the fully accurate concentration as 50 Units/50 mL (1 Unit/mL)

Terminated Labeling / mix-up Advanced Pharma Inc. D-0430-2019
Class III · Low risk

Loperamide HCL Tablets USP

Labeling Not Elsewhere Classified: The front panel indicates 24 caplets whereas the side panel indicates 12 caplets. The drug product carton contains 24 caplets.

Terminated Labeling / mix-up Sun Pharmaceutical Industries, Inc. D-0391-2019
Class I · High risk

Dyural-80 Injection Kit

Labeling: Not eslewhere classified - The kits include Sodium Chloride, USP, 0.9% which was recalled by the manufacturer due to the product insert incorrectly stating stoppers do not contain latex. The stoppers contain natural rubber latex

Terminated Labeling / mix-up Asclemed USA Inc. dba Enovachem NDC 76420-0755-01 D-0354-2019
Class I · High risk

Dyural-40 Injection Kit

Labeling: Not eslewhere classified - The kits include Sodium Chloride, USP, 0.9% which was recalled by the manufacturer due to the product insert incorrectly stating stoppers do not contain latex. The stoppers contain natural rubber latex

Terminated Labeling / mix-up Asclemed USA Inc. dba Enovachem NDC 76420-0750-01 D-0353-2019
Class I · High risk

Phenylephrine HCl

Labeling: Label Error on Declared Strength: Label incorrectly lists concentration as "10 mcg per mL" rather than the correct concentration of "100 mcg per mL".

Terminated Labeling / mix-up Advanced Pharma Inc. D-0347-2019
Class I · High risk

Sodium Chloride Injection

Labeling Not Elsewhere Classified: Fresenius Kabi is taking this action due to an incorrect statement on the product insert for product codes 918610 and 918620 indicating that the stoppers do not contain natural rubber latex. The tray label for these two product codes and the vial label for product code 918620 also incorrectly state that the stoppers do not contain latex. The above listed product codes and batches being recalled have stoppers containing natural rubber latex.

Terminated Labeling / mix-up Fresenius Kabi USA, LLC NDC 63323-186-20 D-0299-2019
Class I · High risk

Sodium Chloride Injection

Labeling Not Elsewhere Classified: Fresenius Kabi is taking this action due to an incorrect statement on the product insert for product codes 918610 and 918620 indicating that the stoppers do not contain natural rubber latex. The tray label for these two product codes and the vial label for product code 918620 also incorrectly state that the stoppers do not contain latex. The above listed product codes and batches being recalled have stoppers containing natural rubber latex.

Terminated Labeling / mix-up Fresenius Kabi USA, LLC NDC 63323-186-10 D-0298-2019
Class II · Moderate risk

Medi-Stat Foam

Labeling: Label mix-up - the label on the product may not match the formula in the bottle.

Terminated Labeling / mix-up Ecolab Inc NDC 47593-503-59 D-0275-2019
Class II · Moderate risk

Equi-Soft Foam

Labeling: Label mix-up - the label on the product may not match the formula in the bottle.

Terminated Labeling / mix-up Ecolab Inc NDC 47593-521-41 D-0274-2019
Class II · Moderate risk

Curaplex Epi Kit NOT FOR IV USE

Labeling Incorrect Instructions: This recall has been initiated because the Instructions for Use included in the Epi-Safe Kits for the Epi-Safe Syringe (and/or the Safety Lok Syringe in Model 8600-01120) recommend a midpoint dosage of epinephrine for children between 0 lbs. and 66 lbs. of 0.15mL that has not been approved by FDA for children. Reliance on the current IFU and/or use of the Epi-Safe Syringe as instructed may result in the administration of an inappropriate dosage of epinephrine to young children experiencing anaphylaxis, especially those under 33 lbs. Additionally the Epi Safe syringe does not have the correct markings to allow a health care provider to draw up the correct dosage for children under 33 kg.

Terminated Labeling / mix-up Bound Tree Medical, LLC D-0386-2019
Class II · Moderate risk

Curaplex Epi Safe Kit

Labeling Incorrect Instructions: This recall has been initiated because the Instructions for Use included in the Epi-Safe Kits for the Epi-Safe Syringe (and/or the Safety Lok Syringe in Model 8600-01120) recommend a midpoint dosage of epinephrine for children between 0 lbs. and 66 lbs. of 0.15mL that has not been approved by FDA for children. Reliance on the current IFU and/or use of the Epi-Safe Syringe as instructed may result in the administration of an inappropriate dosage of epinephrine to young children experiencing anaphylaxis, especially those under 33 lbs. Additionally the Epi Safe syringe does not have the correct markings to allow a health care provider to draw up the correct dosage for children under 33 kg.

Terminated Labeling / mix-up Bound Tree Medical, LLC D-0385-2019
Class II · Moderate risk

curaplex Epi Safe Kit

Labeling Incorrect Instructions: This recall has been initiated because the Instructions for Use included in the Epi-Safe Kits for the Epi-Safe Syringe (and/or the Safety Lok Syringe in Model 8600-01120) recommend a midpoint dosage of epinephrine for children between 0 lbs. and 66 lbs. of 0.15mL that has not been approved by FDA for children. Reliance on the current IFU and/or use of the Epi-Safe Syringe as instructed may result in the administration of an inappropriate dosage of epinephrine to young children experiencing anaphylaxis, especially those under 33 lbs. Additionally the Epi Safe syringe does not have the correct markings to allow a health care provider to draw up the correct dosage for children under 33 kg.

Terminated Labeling / mix-up Bound Tree Medical, LLC D-0384-2019
Class II · Moderate risk

curaplex Epi Safe Administration and Training Kits

Labeling Incorrect Instructions: This recall has been initiated because the Instructions for Use included in the Epi-Safe Kits for the Epi-Safe Syringe (and/or the Safety Lok Syringe in Model 8600-01120) recommend a midpoint dosage of epinephrine for children between 0 lbs. and 66 lbs. of 0.15mL that has not been approved by FDA for children. Reliance on the current IFU and/or use of the Epi-Safe Syringe as instructed may result in the administration of an inappropriate dosage of epinephrine to young children experiencing anaphylaxis, especially those under 33 lbs. Additionally the Epi Safe syringe does not have the correct markings to allow a health care provider to draw up the correct dosage for children under 33 kg.

Terminated Labeling / mix-up Bound Tree Medical, LLC D-0383-2019
Class III · Low risk

Curaplex Epi Safe Kit

Labeling: Incorrect or missing Lot and/or Exp Date:The Kit is incorrectly labeled as expiring May 2018 however the correct expiration date is May 2019. In addition, device component (syringe) lacks 510(k) clearance.

Terminated Labeling / mix-up Bound Tree Medical, LLC D-0379-2019
Class II · Moderate risk

curaplex Epi Safe Administration and Training Kits # 8600-01100…

Labeling: Incorrect or Missing Lot and/or Exp date: vials of epinephrine within kit 8600-01100 expired on December 2018, but the outer kit label has an expiration date of January 2020. In addition, device component (syringe) may lack 510(k) clearance.

Terminated Labeling / mix-up Bound Tree Medical, LLC D-0371-2019

Recalls by year